Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
Titel:
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
Auteur:
Bidard, François-Clément Hardy-Bessard, Anne-Claire Dalenc, Florence Bachelot, Thomas Pierga, Jean-Yves de la Motte Rouge, Thibault Sabatier, Renaud Dubot, Coraline Frenel, Jean-Sébastien Ferrero, Jean Marc Ladoire, Sylvain Levy, Christelle Mouret-Reynier, Marie-Ange Lortholary, Alain Grenier, Julien Chakiba, Camille Stefani, Laetitia Plaza, Jérôme Edouard Clatot, Florian Teixeira, Luis D'Hondt, Véronique Vegas, Hélène Derbel, Olfa Garnier-Tixidre, Claire Canon, Jean-Luc Pistilli, Barbara André, Fabrice Arnould, Laurent Pradines, Anne Bièche, Ivan Callens, Céline Lemonnier, Jérôme Berger, Frédérique Delaloge, Suzette